Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US

24 Oct 2018 Evaluate

Sun Pharmaceutical Industries has launched its plaque psoriasis treatment drug ‘ILUMYA’ (tildrakizumab-asmn) 100 mg/mL in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the USFDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.